|
CXORF56 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.42160000005109E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.24349999999873E-05 |
| Normal-vs-Stage2 |
8.240600E-04 |
| Normal-vs-Stage3 |
1.73465999999678E-05 |
| Normal-vs-Stage4 |
1.91940000004998E-06 |
| Stage1-vs-Stage2 |
8.680200E-01 |
| Stage1-vs-Stage3 |
5.001000E-01 |
| Stage1-vs-Stage4 |
2.219400E-01 |
| Stage2-vs-Stage3 |
7.673000E-01 |
| Stage2-vs-Stage4 |
4.090400E-01 |
| Stage3-vs-Stage4 |
5.091200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.49780000002764E-06 |
| Normal-vs-AfricanAmerican |
3.257200E-01 |
| Normal-vs-Asian |
1.161950E-03 |
| Caucasian-vs-AfricanAmerican |
2.626000E-02 |
| Caucasian-vs-Asian |
6.868600E-01 |
| AfricanAmerican-vs-Asian |
1.090620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.52509999576489E-08 |
| Normal-vs-Female |
4.06379999999817E-05 |
| Male-vs-Female |
2.146200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.412970E-04 |
| Normal-vs-Age(41-60Yrs) |
2.48789999999222E-05 |
| Normal-vs-Age(61-80Yrs) |
7.84929999997352E-07 |
| Normal-vs-Age(81-100Yrs) |
3.516800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.389800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.929780E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.247000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.885000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.640800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.829400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.253600E-02 |
| Classical-VS-Follicular |
6.482800E-03 |
| Classical-VS-Other |
6.707600E-02 |
| Classical-VS-Normal |
2.373100E-04 |
| Tall-VS-Follicular |
9.518800E-01 |
| Tall-VS-Other |
3.108800E-01 |
| Tall-VS-Normal |
4.0923000000026E-05 |
| Follicular-VS-Other |
4.040600E-01 |
| Follicular-VS-Normal |
9.29249999948034E-07 |
| Other-VS-Normal |
1.304830E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.61280000005237E-06 |
| Normal-vs-N1 |
1.16409999995071E-06 |
| N0-vs-N1 |
1.063800E-01 |
|
|
